A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab

References

• Smith L, McCourt O, Henrich M, et al. Multiple myeloma and physical activity: a scoping review. BMJ Open. 2015;5(11):e009576. doi: 10.1136/bmjopen-2015-009576
   PubMed Web of Science ®Google Scholar
• Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52. doi: 10.1186/s13045-016-0282-1
   PubMed Web of Science ®Google Scholar
• Raedler LA. Darzalex (Daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature):70–73.
   PubMedGoogle Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448. doi: 10.1038/leu.2017.138
   PubMed Web of Science ®Google Scholar
• McKeage K. Daratumumab: First Global Approval[J]. Drugs. 2016;76(2):275–281. doi: 10.1007/s40265-015-0536-1
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290–4300. doi: 10.1158/1078-0432.CCR-16-3192
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Sanchorawala V. Daratumumab in AL amyloidosis. Blood. 2022;140(22):2317–2322. doi: 10.1182/blood.2021014613
   PubMedGoogle Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560. doi: 10.1016/S0140-6736(15)01120-4
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with Daratumumab, Bortezomib, and dexamethasone in Previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600–1609. doi: 10.1200/JCO.21.02734
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with Daratumumab, lenalidomide, and dexamethasone in Previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590–1599. doi: 10.1200/JCO.22.00940
   PubMed Web of Science ®Google Scholar
• Kiss S, Gede N, Hegyi P, et al. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2021;11(1):21916. doi: 10.1038/s41598-021-01440-x
   PubMed Web of Science ®Google Scholar
• Chong LL, Soon YY, Soekojo CY, et al. Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103211. doi: 10.1016/j.critrevonc.2020.103211
   PubMed Web of Science ®Google Scholar
• Sun C, Wang X, Zhang R, et al. Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis. Cancer Cell Int. 2022 Jul 4;22(1):222. doi: 10.1186/s12935-022-02635-6
   PubMed Web of Science ®Google Scholar
• Shu Y, He X, Liu Y, et al. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789–802. doi: 10.2147/CLEP.S365513
   PubMed Web of Science ®Google Scholar
• Chen C, Wu B, Zhang C, et al. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021;95:107498. doi: 10.1016/j.intimp.2021.107498
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219. doi: 10.1056/NEJMoa1506348
   PubMed Web of Science ®Google Scholar
• Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(11):ofac574. doi: 10.1093/ofid/ofac574
   PubMed Web of Science ®Google Scholar
• Vitkon R, Netanely D, Levi S, et al. Daratumumab in combination with prote some inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. Ther Adv Hematol. 2021;12:20406207211035272. doi: 10.1177/20406207211035272
   Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Worth LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100–108. doi: 10.1111/bjh.13532
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Lee AC, Greaves G, Lee R, et al. Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma. J Glaucoma. 2018;27(9):e145–e147. doi: 10.1097/IJG.0000000000000995
   PubMed Web of Science ®Google Scholar
• Saengsirinavin AO, Wutthayakorn W, Chansangpetch S, et al. Acute bilateral angle closure induced by monoclonal antibody (daratumumab) infusion. Am J Ophthalmol Case Rep. 2021;22:101079. doi: 10.1016/j.ajoc.2021.101079
   PubMedGoogle Scholar
• Edwards RG, Vanderhoof S, Palestine A, et al. Bilateral secondary angle closure during daratumumab infusion: a case report and review of the literature. J Glaucoma. 2020;29(8):e83–e86. doi: 10.1097/IJG.0000000000001562
   PubMed Web of Science ®Google Scholar
• Rasmussen PK, Kiilgaard JF, Salomo M. Association of choroidal effusion and infusion of Daratumumab. JAMA Ophthalmol. 2019;137(7):853–854. doi: 10.1001/jamaophthalmol.2019.1427
   PubMed Web of Science ®Google Scholar
• Strong A, Huvard M, Olson JL, et al. Daratumumab-induced choroidal effusion: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2020;20(12):e994–e997. doi: 10.1016/j.clml.2020.08.030
   PubMed Web of Science ®Google Scholar
• Woods A, Wooten M, Thompson Heffner L Jr, et al. Daratumumab-associated hemophagocytic lymphohistiocytosis. Ann Hematol. 2020;99(1):181–182.
   PubMed Web of Science ®Google Scholar
• Horenstein AL, Sizzano F, Lusso R, et al. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.Mol med. Mol Med. 2009;15(3–4):76–84. doi: 10.2119/molmed.2008.00108
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. Darzalex product monograph. 2022 [cited 2022 Apr 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761036s041lbl.pdf
   Google Scholar
• Janssen Biotech Inc. Darzalex faspro product monograph. 2022 [cited 2022 Apr 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761145s012lbl.pdf
   Google Scholar
• Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541–1547. doi: 10.1182/blood.2019004436
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Kareem SS, Viswanathan N, Sahebjam S, et al. Leukoencephalopathy during daratumumab-based therapy: a case series of two patients with multiple myeloma. Onco Targets Ther. 2022;15:953–962. doi: 10.2147/OTT.S365657
   PubMed Web of Science ®Google Scholar
• Guerreiro S, Privat AL, Bressac L, et al. CD38 in Neurodegeneration and Neuroinflammation. Cells. 2020;9(2):471. doi: 10.3390/cells9020471
   PubMed Web of Science ®Google Scholar
• Yelehe-Okouma M, Czmil-Garon J, Pape E, et al. Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol. 2018;32(3):252–260. doi: 10.1111/fcp.12349
   PubMed Web of Science ®Google Scholar
• Ulrich A, Weiler S, Weller M, et al. Cetuximab induced aseptic meningitis. J Clin Neurosci. 2015;22(6):1061–1063. doi: 10.1016/j.jocn.2014.11.034
   PubMed Web of Science ®Google Scholar
• Junga Z, Theeler B, Singla M. Infliximab-induced aseptic meningitis in a patient with crohnʼs disease. ACG Case Rep J. 2018;5(1):e48. doi: 10.14309/crj.2018.48
   PubMedGoogle Scholar
• Maritaz C, Metz C, Baba-Hamed N, et al. Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event. BMC Cancer. 2016;16(1):384. doi: 10.1186/s12885-016-2434-7
   PubMedGoogle Scholar
• Park SS, Min Byun J, Yoon SS, et al. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. Br J Haematol. 2021;193(1):101–112. doi: 10.1111/bjh.17071
   PubMed Web of Science ®Google Scholar